Steroid of Choice for Ménière's Disease with Acute Onset Hearing Loss
For Ménière's disease with acute onset hearing loss, use intratympanic dexamethasone (4-24 mg/mL) or methylprednisolone (≥30 mg/mL), with methylprednisolone showing superior hearing improvement in comparative studies. 1, 2
Route of Administration
The 2020 AAO-HNS guideline specifically addresses Ménière's disease and recommends intratympanic steroids as the appropriate route for this condition 1. This differs from sudden sensorineural hearing loss (SSNHL) guidelines, which primarily recommend oral steroids. The intratympanic route bypasses the blood-labyrinthine barrier to achieve higher concentrations in the inner ear 3.
Specific Steroid Selection
Primary Options:
- Dexamethasone: 4-24 mg/mL (higher concentrations produce better results) 3, 4
- Methylprednisolone: ≥30 mg/mL or 40 mg/mL 3, 4
Evidence Favoring Methylprednisolone:
A 2017 randomized trial directly comparing these agents in 69 patients with definite Ménière's disease found that intratympanic methylprednisolone (40 mg/dL) produced statistically significantly greater hearing improvement compared to dexamethasone (4 mg/dL) (P=0.006), though both were equally effective for vertigo control 2. This represents the highest quality comparative evidence available.
Treatment Protocol
Dosing schedule: Three weekly injections 2
Technique:
- Anterosuperior myringotomy after topical anesthetic 4
- Patient remains at rest for 15-30 minutes post-injection 3
Monitoring: Audiogram before each subsequent injection, at completion of treatment, and at delayed intervals 4
Critical Distinction from SSNHL
This question specifically asks about Ménière's disease, not idiopathic sudden sensorineural hearing loss. While the provided evidence extensively discusses SSNHL treatment (which favors oral prednisolone 1 mg/kg/day, maximum 60 mg daily for 10-14 days) 3, the Ménière's disease guideline explicitly recommends intratympanic rather than oral steroids 1.
Important Caveats
Nomenclature precision matters: When using dexamethasone or methylprednisolone intratympanically, you are actually administering dexamethasone-phosphate or methylprednisolone-hemisuccinate, which have completely different pharmacokinetic properties than the base compounds 5. This affects drug entry into and elimination from perilymph.
Evidence limitations: The overall certainty of evidence for intratympanic steroids in Ménière's disease is low to very low 6. A 2023 Cochrane review found that intratympanic dexamethasone may slightly reduce vertigo frequency but noted concerns about publication bias and unpublished negative trials 6. However, given the potential for permanent hearing impairment and quality of life impact, treatment remains reasonable 1.
Timing: Treatment should be offered during active disease, particularly for patients not responsive to conservative management 1.